Do Not Sell My Data

Mirum Pharmaceuticals, Inc. complies with the California Consumer Privacy Act (“CCPA”), which gives California residents the right to opt out of the “sale” of their personal information that we collect from their use of our site.

Mirum does not sell your personal information for money to anyone. However, the definition of “sale” under the CCPA is very broad and therefore may include certain types of sharing.

If you have questions regarding this form or have difficulty accessing it, please contact us at privacy@mirumpharma.com.

Please note: a separate form will need to be submitted for each request.

Submit Your Privacy Request

*Required field.

Thank you for submitting your request!

YIKES!
We're having some connection trouble.

Please refresh the page and try submitting your form again. If the issue persists, please contact us.

expand btn collapse btn

Indication

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 3 months of age and older. It is not known if LIVMARLI is safe and effective in children under 3 months of age or in adults 65 years and older.

Important Safety Information

What are the possible side effects 
of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were gastrointestinal bleeding and bone fractures.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information: English | Español